CRDF Earnings Prediction
The chart below shows how CRDF performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CRDF sees a -3.04% change in stock price 10 days leading up to the earnings, and a +17.12% change 10 days following the report. On the earnings day itself, the stock moves by +0.33%. This data can give you a slight idea of what to expect for the next quarter's release.
CRDF Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
163.00K
50.93%
-20.49%
Gross Margin
--
--
--
Operating Margin
-7696.32%
-31.91%
44.31%
Net Margin
-7225.77%
-30.01%
47.97%
EPS
-0.26
-4.00%
18.18%
No Data Available
CRDF Earnings Analysis
Cardiff Oncology, Inc. Common Stock Corporation (CRDF.O) Earnings Conference Call
Positive
Cardiff Oncology is actively enrolling patients in the CRDF-004 trial for RAS-mutated metastatic colorectal cancer with promising initial data readout expected later this year, reinforcing the potential of onvansertib to bring a more effective therapy to this patient population.
The company has adapted its pancreatic cancer program to support a first-line investigator-initiated trial combining onvansertib with NALIRIFOX, aligning with the new first-line standard of care and demonstrating flexibility in addressing evolving treatment protocols.
Cardiff Oncology continues to identify other cancer indications where onvansertib may be clinically efficacious, showcasing promising preclinical data in ovarian cancer resistant to PARP inhibitors and highlighting the potential of onvansertib to overcome resistance in this high-grade serious ovarian carcinoma.
The company's financial update shows a solid balance sheet with $60.3 million in cash and short-term investments as of June 30, 2024, providing runway through the end of the third quarter of 2025, demonstrating financial stability to support ongoing clinical development efforts.
Negative
- Cash used in operating activities was $9.2 million in Q2 2024, indicating a significant financial burden on the company.
- The change in the first-line standard of care for pancreatic cancer to NALIRIFOX has led to a shift in the company's clinical trial plans, impacting the development timeline and strategy.
- No therapies have been approved for RAS-mutated mCRC patients in the past 20 years, highlighting a lack of innovation and treatment options in this area.
- The company faces the challenge of overcoming resistance to PARP inhibitors in ovarian cancer, which could impact the effectiveness of onvansertib in this indication.
CRDF FAQs
How does CRDF typically perform around its earnings report dates?
Is Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CRDF Earning Call Sentiment
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
CRDF.O
-1.13%Positive
The earnings call summary presents a mixed outlook. Financials show a stable cash position with a runway until Q3 2025, but high cash usage raises financial sustainability concerns. Clinical developments are promising, particularly in mCRC and ovarian cancer, yet regulatory and competitive risks loom large. The Q&A session reveals steady trial enrollment and strategic partnerships, but lacks clarity on scientific validation. Overall, the balance of positive clinical updates and financial/market risks suggests a neutral stock price movement in the near term.